Literature DB >> 12529997

Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.

E Ragazzi1, S D'Ancona, E Berti, M Carrara.   

Abstract

In vitro synergy has been reported for exposure to paclitaxel prior to cis-platin (cis-DDP), whereas the reverse sequence resulted in antagonism. There is no clear evidence for an intracellular origin of the schedule-dependent interaction, but several hypotheses have been proposed, such as effects at the level of DNA crosslinks, or binding to tubulin sites. The purpose of this study was to evaluate the cytotoxicity of these two drugs as single agents, in combination and in sequence, against a human colon adenocarcinoma cell line (LoVo). Moreover, we considered the new Pt-mercaptopyridine complex C/2, was like cis-platin in being able to alter DNA conformation. We have therefore studied the cytotoxic effects after single agent exposure, concomitant exposure (paclitaxel + cis-platin and paclitaxel + C/2) and sequential drugs exposure (paclitaxel-->cis-platin and cis-platin-->paclitaxel or paclitaxel-->C/2 and C/2-->paclitaxel). Our results demonstrate that the most cytotoxic effect is induced by paclitaxel and C/2 exposure both in the case of concomitant cell treatment and sequential exposure paclitaxel-->C/2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529997

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.

Authors:  Gisele A Sarosy; Mahrukh M Hussain; Michael V Seiden; Arlan F Fuller; Najmosama Nikrui; Annekathryn Goodman; Lori Minasian; Eddie Reed; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.